



RESEARCH TOPIC CLI24

The Role of Innovative Therapies as Disease-Modifying in Inflammatory Skin Diseases: Identification of Minimal Disease Activity Parameters and Long-term Remission

Research Area

Medical Area

Clinical Unit name

Dermatology Unit, IRCCS Humanitas

Supervisor

Antonio Costanzo antonio.costanzo@hunimed.eu

Abstract

In recent years, the introduction of biologics and small molecules has revolutionized the long-term treatment of inflammatory skin diseases. Despite these advances, the specific role of these innovative treatments, particularly as modifiers of natural history in inflammatory skin diseases (including psoriasis vulgaris, atopic dermatitis, alopecia areata and chronic spontaneous urticaria), remains to be fully defined.

This project aims to identify the criteria for minimal disease activity in different inflammatory skin diseases and to elucidate the etiopathogenetic and pathophysiological mechanisms underlying the long-term remission of these diseases under these innovative therapies.

To achieve these goals, the project will include the analysis of clinical trial and real-world registry data.

Scientific references

- 1 Schäkel K, Reich K, Asadullah K, et al. Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study. *J Eur Acad Dermatol Venereol.* 2023;37(10):2016-2027. doi:10.1111/jdv.19236
1. doi:10.3390/ijms21051690
- 2 Bieber T. Disease modification in inflammatory skin disorders: opportunities and challenges [published correction appears in *Nat Rev Drug Discov.* 2023 Nov;22(11):935]. *Nat Rev Drug Discov.* 2023;22(8):662-680. doi:10.1038/s41573-023-00735-0
- 3 Carretero G, Carrascosa JM, Puig L, et al. Definition of minimal disease activity in psoriasis. *J Eur Acad Dermatol Venereol.* 2021;35(2):422-430. doi:10.1111/jdv.16564
- 4 Gargiulo L, Ibba L, Malagoli P, et al. A risankizumab super responder profile identified by long-term real-life observation-IL PSO (ITALIAN LANDSCAPE PSORIASIS). *J Eur Acad*

Dermatol Venereol.
doi:10.36849/JDD.2020.5337

2024;38(1):e113-e116.

doi:10.1111/jdv.19464

5 Merola JF, McInnes IB, Deodhar AA, et al. Effect of Secukinumab on Traditional Cardiovascular Risk Factors and Inflammatory Biomarkers: Post Hoc Analyses of Pooled Data Across Three Indications. *Rheumatol Ther.* 2022;9(3):935-955

6 Lé AM, Torres T. OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis-Focus on Rocatinlimab and Amlitelimab. *Pharmaceutics.* 2022;14(12):2753. Published 2022 Dec 8. doi:10.3390/pharmaceutics14122753

Type of contract

Contract for continuative and coordinated service of at least € 26.000 activated Istituto Clinico Humanitas. This sum is subject to IRPEF income tax.

Contratto collaborazione coordinata e continuativa (cococo) pari ad almeno € 26.000 annui lordi attivato da Istituto Clinico Humanitas. Importo soggetto a tassazione IRPEF.